A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
This study is for people with multiple myeloma, a type of blood cancer. It tests if two medicines, elranatamab (given as a shot) and iberdomide (a pill), work well together. The goal is to find out the safest amount to give. The study has two parts: Part 1 checks safety, and Part 2 finds the right dose. Participants will take these medicines in a 28-day cycle until the disease worsens, they experience bad side effects, or decide to stop. This study could help find new treatments for multiple myeloma.
- The study lasts as long as you can tolerate the medicines or until the disease progresses.
- Medicine is given in 28-day cycles: a shot and a pill.
- Participants can leave the study any time if they wish.
Study details
NCT06215118
Pfizer
11 July 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.